As EGFR-tyrosine kinase inhibitor (TKI) can provide a better efficacy and quality of life to the patients, it has emerged as one of the most important therapies among non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations [6–8]. Here, EGFR is linked to non-small cell lung carcinoma.